EDDA Technology

  
EDDA’s IQQA-Liver for multi-phase contrast CT 
EDDA Technology (Booth 203) is premiering the new release of its IQQA-Liver Enterprise solution as well as demonstrating the capabilities of its IQQA-Chest Enterprise system.
 
The new release of IQQA-Liver Enterprise provides an innovative toolset for physician’s fast real-time assessment of volumetry of liver, liver lobes and segments, hepatic lesions, and vascular structures from CT. This workflow volumetric evaluation is powered by the integration of automatic computer analysis and the real-time interactive 2D/3D editing capabilities for users.

The system performs automatic anatomic phase registration to allow simultaneous visualization and cross-referencing of lesion location and characteristics across the different phases. IQQA-Liver further provides automated segmentation tools and additional multiple real-time interactive tools for the segmentation and refinement of liver, vessels, lesions, liver lobes and segments. Quantitative measurements are extracted from segmented and labeled volumes instantly.

IQQA-Liver Enterprise is available to work on a facility’s existing PACS workstations without code level or application programming interface (API) integration, EDDA says.

IQQA-Chest Enterprise offers a new generation enterprise computer aided detection (CAD) solution for chest DR/CR. It provides a comprehensive set of real-time interactive tools to support physicians in the identification, confirmation and quantification of lung nodules.

 IQQA-Chest Enterprise offers the advantage of quick installation and easy maintenance in hospital’s existing PACS environment without code level or API integration. The option of floating licenses for IQQA-Chest Enterprise is also available from the firm.

Around the web

The new technology shows early potential to make a significant impact on imaging workflows and patient care. 

Richard Heller III, MD, RSNA board member and senior VP of policy at Radiology Partners, offers an overview of policies in Congress that are directly impacting imaging.
 

The two companies aim to improve patient access to high-quality MRI scans by combining their artificial intelligence capabilities.